Pfizer Inc (NYSE:PFE) has reaffirmed its commitment to openly sharing research findings related to its COVID-19 vaccine, while ensuring the ongoing studies maintain scientific rigor.

In a statement, Pfizer Chairman and CEO Dr. Albert Bourla recognized the accomplishments of Operation Warp Speed under President Trump, emphasizing that American innovation helped avert economic collapse and saved over 14 million lives worldwide.

Bourla highlighted that the initiative restored consumer confidence, cut over $1 trillion in healthcare costs by reducing severe illness and hospitalizations, and rapidly expanded domestic vaccine production. He also noted that the mRNA platform could lead to significant advances in cancer research.

“President Trump’s call for transparency is welcomed, and we remain deeply committed to that principle,” Bourla said. “Transparency has always been a cornerstone of trust, and we are dedicated to continuing to provide clear, factual data to the public.”

Pfizer emphasized that data on its COVID-19 vaccine has been featured in over 600 peer-reviewed publications and submitted to regulators in 130 countries, all of which approved the vaccine following review.

The company also pointed out that several nations—including the United Kingdom, Denmark, Israel, and Turkey—have produced real-world evidence through their vaccination campaigns, further validating the vaccine’s safety and effectiveness.

In response to President Trump’s request, Pfizer provided a website link containing published studies and safety data and announced plans to post additional information by the end of the month, including new data on its latest FDA-approved vaccine strain.

The announcement comes after Trump’s recent social media post urging pharmaceutical companies to justify the success of their COVID-19 vaccines and share data with the public and the CDC.

Pfizer stock price

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Join the discussion: Connect with other investors on your favorite stocks or explore the top-talked-about stocks on our Breakout Boards.

This article was written by the editorial team at InvestorsHub/ADVFN and is provided for informational purposes only. In some cases, editorial staff may use artificial intelligence–based tools to assist in the research, drafting, or editing of content, under human review and oversight. This article does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. The views expressed are based on publicly available information believed to be reliable at the time of publication, but accuracy or completeness is not guaranteed. Readers should conduct their own independent research and consult a qualified financial professional before making any investment decisions.